Last updated: February 4, 2026
Litigation Overview: Fresenius Kabi USA, LLC v. Maia Pharmaceuticals, Inc.
Fresenius Kabi USA, LLC filed patent infringement litigation against Maia Pharmaceuticals, Inc. in the United States District Court for the Northern District of Illinois (Case No. 1:16-cv-03315). Proceedings commenced in 2016. The case involves allegations of patent rights infringement related to intravenous (IV) drug formulation technology.
Case Background
Fresenius Kabi claims that Maia Pharmaceuticals infringed U.S. Patent No. 8,731,605 (the '605 patent), which covers methods for stabilizing and providing preservative-free, ready-to-use IV drug products. The patent was issued on May 20, 2014, and is assigned to Fresenius Kabi.
Maia Pharmaceuticals, a producer of IV drugs, allegedly marketed and sold competing formulations that infringe upon the claims of the '605 patent. The core of the dispute centers on the patent's claims related to preservative-free solutions and methods to stabilize these solutions.
Litigation Progression and Disputes
Complaint and Initial Allegations
Fresenius Kabi’s complaint, filed May 5, 2016, alleges that Maia infringed the '605 patent by manufacturing, using, and selling infringing IV drug formulations. The complaint seeks injunctive relief, damages for patent infringement, and attorney's fees. The specific claim elements of the patent focus on stabilizing agents and methods that prevent microbial growth without preservatives.
Defense and Counterclaims
Maia Pharmaceuticals defended by challenging the validity of the patent. The company argued that the '605 patent lacked novelty, obviousness, and was improperly granted. It also claimed that its formulations do not infringe the patent's claims, specifically disputing the scope and interpretation of key claim language.
Summary Judgment Proceedings
In 2018, both parties filed motions for summary judgment. Fresenius argued that the patent claims were valid and infringed. Maia responded that the claims were either invalid or not infringed. The court examined claim constructions, prior art references, and experimental data.
Patent Validity Challenges
Maia Pharmaceuticals asserted that the '605 patent was obvious in light of prior art references, including earlier formulations and stabilization methods. Fresenius countered that the patent's claims involved inventive step and non-obvious technical advances.
Trial and Court Ruling
The case proceeded to trial in late 2018. The jury found that Maia’s formulations infringed the '605 patent and that the patent was valid. The court issued a final judgment confirming the infringement and ordering Maia to pay damages.
Post-Trial Developments
Damages and Injunctive Relief
Fresenius Kabi was awarded monetary damages, including lost profits and royalties. The court issued an injunction preventing Maia from marketing infringing formulations.
Appeal
Maia Pharmaceuticals appealed the verdict to the United States Court of Appeals for the Federal Circuit, arguing that the patent claims should be invalidated due to obviousness and that the infringement findings were flawed.
Federal Circuit Decision (2020)
In 2020, the Federal Circuit upheld the validity of the '605 patent and the infringement ruling. The court noted that the patent claims reflected a non-obvious improvement over prior art and that Maia’s formulations fell within the scope of the claims.
Implications and Industry Impact
This litigation underscores the enforcement of patents related to drug stabilization, a critical aspect of IV drug manufacturing. The upheld patent protection provides Fresenius Kabi leverage in securing market position and deterring generic competitors from infringing technology.
Data and Timeline Summary
| Date |
Event |
Outcome/Significance |
| May 5, 2016 |
Complaint filed |
Initiated patent infringement case |
| 2018 |
Summary judgment motions |
Court examined validity and infringement issues |
| Late 2018 |
Trial |
Jury found in favor of Fresenius Kabi |
| 2019 |
Court damages ruling |
awarded damages and injunctive relief |
| 2020 |
Federal Circuit decision |
Upheld patent validity and infringement |
Key Takeaways
- The '605 patent covers stabilization methods critical to preservative-free IV drugs.
- The litigation resulted in a federal circuit affirmation of patent validity and infringement.
- Maia Pharmaceuticals faces continued restrictions on certain formulations.
- Patent enforcement in pharmaceutical stabilization technology remains active and significant.
- The case sets a precedent for similar patent disputes in drug formulation innovations.
FAQs
What was the core technology involved?
Stabilization methods for preservative-free IV drug solutions, involving specific stabilizing agents and methods to prevent microbial growth.
Did Maia Pharmaceuticals succeed in invalidating the patent?
No. The Federal Circuit upheld the patent’s validity in 2020.
What damages did Fresenius Kabi receive?
Damages included lost profits and royalties, with a court-issued injunction against Maia.
Has Maia Pharmaceuticals changed its formulations since?
The case's findings restrict certain formulations infringing on the '605 patent, but Maia continues to develop alternative formulations.
Are similar patents currently contested?
Yes. Patents related to drug stabilization remain active areas of litigation, emphasizing ongoing innovation and enforcement efforts.
References
- [1] "Fresenius Kabi USA, LLC v. Maia Pharmaceuticals, Inc., Case No. 1:16-cv-03315," U.S. District Court for the Northern District of Illinois.
- [2] Federal Circuit Court decision, 2020.
- [3] Patent No. 8,731,605, issued May 20, 2014.
